Cells have surface receptors called integrins that bind to repetitive domains present on the extracellular matrix (ECM) surrounding the cells, allowing them to grow and spread. A new study from the ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

In the face of rising concerns about antibiotic resistant infections, an international group of microbial experts have launched a powerful and flexible free online genomic toolkit for more rapid ...

Protein complex in bacterial cell membrane acts like a rotary motor to recruit DNA-degrading enzymes to defend against phage ...

1Jiangxi Key Laboratory of Oncology, JXHC Key Laboratory of Tumor Metastasis, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Jiangxi Cancer Institute, Nanchang, ...

PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...

Thibaut du Fayet, Chief Executive Officer of PHAXIAM, stated: “We start 2025 with a clear ambition to position PHAXIAM as a Specialty Pharma in Critical care, in the booming phage therapy market.

a risk factor for cancer. Renaming DCIS is an “ethical imperative,” she has argued, to spare patients undue anxiety and to shift the current treatment paradigm from invasive surgery to active ...

"The number of patients who achieved this pCR improved significantly as a result of nivolumab, an exciting result that points to a new treatment paradigm in this most common type of breast cancer." ...

The study was published in the top journal Nature Cancer. In the study Talimogene Laherparepvec (TVEC) was used, which has so far only been approved for the treatment of superficial melanoma ...

The second CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" for blood cancer patients. Listen to Story Qartemi is India's second CAR-T cell therapy ...

New York, USA, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight The phage therapy market is ...